Page 1

Recursion . Recursion Provides Business Updates and Reports Third Quarter 2021 Financials November 10 , 2021 - Received Fast Track Designation for REC - 2282 , a potential treatment for NF2 meningiomas , and expect to enroll the first patient in a Phase 2/3 trial in early 2022 - Advanced REC - 994 , a potential treatment for CCM , and now expect to enroll the first patient in a phase 2 trial in early 2022 - Received Orphan Drug Designation from the FDA for REC - 4881 , a potential treatment for FAP , and expect to enroll the first patient in a Phase 2 trial in the first half of 2022 - Continued to advance multiple simultaneous discovery programs in fibrosis with Bayer - Accelerated investment in the industrialization of chemistry to complement its longstanding work to decode biology SALT LAKE CITY , Nov. 10 , 2021 / PRNewswire / -- Recursion ( Nasdaq : RXRX ) , a clinical - stage biotechnology company decoding biology by integrating technological innovations across biology , chemistry , automation , data science and engineering , today reported business updates and financial results for its third quarter ending September 30 , 2021 . " In Q3 , our team made progress towards our vision to industrialize drug discovery . We are now harvesting the efforts of the past few years to build a map of human cellular biology through the continued refinement and increased usage of our inference - based approach to drug discovery . With the power of our Recursion Map illuminating new and exciting relationships in biology , we are now deeply focused on extending our chemistry capabilities to significantly improve , scale and speed up new chemical entity development to address the plethora of novel biological relationships we are discovering , " said Recursion Co - Founder & CEO Chris Gibson , Ph.D. " In addition , our rapidly growing development team is preparing for our four clinical - stage programs to initiate Phase 2 or Phase 2/3 studies in the first half of 2022 , including two of the programs that we expect will enroll their first patients in early 2022. To facilitate our broad ambition , we continue to rapidly grow our workforce while nurturing Recursion's culture and community . " Stage of Development NEUROFIBROMATOSIS TYPE 2 ( NF2 ; est . 33K³ ) CEREBRAL CAVERNOUS MALFORMATION ( CCM ; 360K7 ) CLINICAL O FAMILIAL ADENOMATOUS POLYPOSIS ( APC ; est . 50K³ ) GM2 GANGLIOSIDOSIS ( HEXA / HEXB ; est . 400 ) PRECLINICAL LATE DISCOVERY O NEUROINFLAMMATION ( Cytokine combo ; est . 13M ) EARLY DISCOVERY 000 5 PROGRAMS Neuroscience 6 TOTAL PROGRAMS OIMMUNE CHECKPOINT RESISTANCE ( STK11 ; 30K * ) O PULMONARY O ONCOLOGY ( MYC , est . 130K ) O HEPATOCELLULAR CARCINOMA O O O O O CANCER IMMUNOTHERAPY TARGET ALPHA CANCER IMMUNOTHERAPY TARGET BETA 00000 000000 0000000 18 PROGRAMS ARTERIAL HYPERTENSION ( BMPR2 ; est . 35K³ ) OCMT TYPE 2A 00 ( MFN2 ; est . 15K³ ) O BATTEN DISEASE ( CLN2 / 3 ; est . 2K³ ) O CLOSTRIDIUM DIFFICILE COLITIS 0 0 ( est . 730K ) O SENOLYTICS ( Multiple ) O Individual Program 00000 3 PROGRAMS 2 PROGRAMS 000000 13 PROGRAMS Oncology Rare Disease Other Inflammation & Immunology 24 TOTAL PROGRAMS 9 TOTAL PROGRAMS 4 TOTAL PROGRAMS 13 TOTAL PROGRAMS Therapeutic Area EU5 is defined as France , Germany , Italy , Spain and the UK . ( 1 ) Our program has the potential to address a number of indications within neuroinflammation , including multiple neurodegenerative diseases totalling at least 13 million patients in the US and EUS . ( 2 ) 730,000 annual incidence in US and EU5 . ( 3 ) Annual US and EU5 prevalence ( 4 ) Worldwide prevalence ( 5 ) Annual US and EU5 incidence for all NF2 - driven meningiomas . ( 6 ) Our program has the potential to address a number of indications driven by MYC alterations , totalling 120,000 patients in the US and EUS annually . We have not finalized a target product profile for a specific indication . ( 7 ) Hereditary and sporadic symptomatic population . Recursion finished the third quarter of 2021 with a portfolio of 4 clinical stage programs , 4 preclinical programs , 7 late discovery programs , and 41 early discovery programs . Additionally , Recursion continued scaling the total number of executed phenomic experiments to approximately 95 million , the size of its proprietary data universe to over 11 petabytes , and the number of biological inferences to approximately 200 billion . Data have been generated on the Recursion OS across 38 human cell types , an in - house chemical library of over 717 thousand compounds , and an in silico library of